NCT04168723 (TQT2) is a Phase 1 clinical trial of MD1003 in Healthy Volunteers, sponsored by MedDay Pharmaceuticals SA.

Who is sponsoring NCT04168723?

NCT04168723 is sponsored by MedDay Pharmaceuticals SA.

What drugs are being tested in NCT04168723?

Interventions in NCT04168723: MD1003, Moxifloxacin 400mg, Placebo for MD1003, Placebo for moxifloxacin.

What condition does NCT04168723 study?

NCT04168723 studies Healthy Volunteers.

Is NCT04168723 still recruiting?

NCT04168723 is currently status unknown. Last updated 20 February 2020.

Last reviewed 2020-02-20 · How we verify

NCT04168723: TQT2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects

Status unknown Phase 1 Last updated 20 February 2020

What this trial tests

Phase 1 trial testing MD1003 in Healthy Volunteers in 64 participants. Status unknown.

Timeline

11 November 2019

Primary endpoint
5 March 2020

5 March 2020

Quick facts

Lead sponsor	MedDay Pharmaceuticals SA
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	other
Enrollment	64
Start date	11 November 2019
Primary completion	5 March 2020
Estimated completion	5 March 2020
Sites	1 location across United Kingdom

Drugs / interventions tested

MD1003 — full drug profile →
Moxifloxacin 400mg — full drug profile →
Placebo for MD1003 — full drug profile →
Placebo for moxifloxacin — full drug profile →

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

MedDay Pharmaceuticals SA — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, single-center, double-blind, randomized, placebo- and positive controlled, double-dummy, parallel-group, repeated-dose study with a nested cross-over comparison between moxifloxacin and placebo to evaluate the effect of MD1003 on cardiac repolarization in healthy adult subjects. The planned enrollment is approximately 64 subjects randomized in a ratio of 1:1 to 2main groups. Subjects in Group B will be further randomized to Subgroups B1 and B2 in a ratio of 1:1.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MD1003

Trials testing the same drug.

NCT04252417 — HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subject · Phase 1 · terminated
NCT04252430 — RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects · Phase 1 · terminated
NCT02967679 — SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study · Phase 2 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other MedDay Pharmaceuticals SA trials

Trials by the same sponsor.

NCT04223232 — Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjects · Phase 1 · completed
NCT04252417 — HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subject · Phase 1 · terminated
NCT04252430 — RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects · Phase 1 · terminated
NCT02967679 — SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04168723 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MedDay Pharmaceuticals SA
Last refreshed: 20 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04168723.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing